Dr. Torti has served as Chairman of our Board since November 2018. Dr. Torti has served as the Vant Chair of Roivant Sciences, Inc. (“RSI”), a wholly-owned subsidiary of Roivant, since January 2020. In this capacity he serves as Chairman, CEO, or Executive Chairman of the board of directors of the biopharmaceutical companies in the Roivant family and is responsible for the operations and management of those companies. From its founding in November 2022 to the close of its sale in December 2023, Dr. Torti served as Chief Executive Officer of Telavant, which was acquired by Roche for over $7 billion. Dr. Torti previously served as Vant Investment Chair of RSI. Prior to joining RSI, Dr. Torti served as a Partner of New Enterprise Associates (“NEA”), specializing in investments in healthcare. Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical &Genetic Economics in various capacities, where he was involved in clinical trials research and economic evaluations of multinational clinical trials.

Dr. Torti presently serves as Executive Chair of the board of directors of Immunovant, Inc. (Nasdaq: IMVT). Dr. Torti previously served on the boards of directors of Urovant Sciences Ltd. and Myovant Sciences Ltd. During his career he has served on the boards of directors of approximately thirty development and commercial stage public and private healthcare companies. Dr. Torti earned an M.D. from the University of North Carolina School of Medicine, an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina.